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Abstract: Background: With the rapid increase in the incidence and mortality of lung cancer, a growing
number of lung cancer patients and their families are faced with a tremendous economic burden
because of the high cost of treatment in China. This study was conducted to estimate the economic
burden and patient responsibility of lung cancer patients and the impact of this burden on family
income. Methods: This study uses data from a retrospective questionnaire survey conducted in
10 communities in urban China and includes 195 surviving lung cancer patients diagnosed over the
previous five years. The calculation of direct economic burden included both direct medical and direct
nonmedical costs. Indirect costs were calculated using the human capital approach, which measures
the productivity lost for both patients and family caregivers. The price index was applied for the cost
calculation. Results: The average economic burden from lung cancer was $43,336 per patient, of which
the direct cost per capita was $42,540 (98.16%) and the indirect cost per capita was $795 (1.84%). Of the
total direct medical costs, 35.66% was paid by the insurer and 9.84% was not covered by insurance.
The economic burden for diagnosed lung cancer patients in the first year following diagnosis was
$30,277 per capita, which accounted for 171% of the household annual income, a percentage that
fell to 107% after subtracting the compensation from medical insurance. Conclusions: The economic
burden for lung cancer patients is substantial in the urban areas of China, and an effective control
strategy to lower the cost is urgently needed.
Keywords: economic burden; lung cancer; direct cost; indirect cost; medical insurance; China
1. Introduction
Lung cancer has been a major public health problem in most countries for several decades. In 2012,
an estimated 1.8 million new cases of lung cancer were diagnosed (12.9% of the total new cancer cases);
58% of these cases occurred in the less developed regions of the world. Lung cancer was the most
common cause of death from cancer worldwide, responsible for an estimated nearly one in five cancer
deaths (1.59 million deaths, 19.4% of the total cancer deaths) [1].
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In China, lung cancer has been the leading cancer diagnosis and the leading cause of cancer
deaths for many years. According to the Chinese National Central Cancer Registry (NCCR), the year
2010 saw 605,946 new lung cancer diagnoses (19.59% of the total cancer cases) in China with a crude
incidence rate of 46.08 per 100,000. Of these diagnoses, the number of cases from urban areas was
348,107 (57.45% of the total new lung cancer cases). With respect to mortality from cancer, an estimated
486,555 people in China died of lung cancer in 2010 with a crude mortality rate of 37.00 per 100,000,
and 279,919 (57.53%) of these patients were from urban areas [2]. The World Health Organization
(WHO) predicted that by 2025, the annual number of new cases of lung cancer mortality in China will
be over one million, and the number of lung cancer patients will be the highest in the world [3].
As the population ages, the expenditure for lung cancer treatment will become even more
burdensome to the entire society [4–6]. To date, a relatively large amount of research has been done on
the economic burden of lung cancer worldwide [7–16]. However, the economic burden of lung cancer
patients varies by country, due to differences in economic development, health systems, exchange rate,
purchasing power, and other factors [5].
Studying the economic burden of lung cancer in China is attracting the attention of more and
more scholars. However, most studies to date have been limited in measuring the direct costs or
hospitalization expenses of lung cancer patients by using data from specific hospitals [17–21]. Moreover,
most previous studies also were limited in calculating short-term costs without considering the cost of
long-term treatment in the years following diagnosis.
According to previous reports, the five-year survival rate of lung cancer patients in China is
reported at 10%–15% [3,18,22]. Estimating the expenditure of lung cancer patients in the first five years
is necessary to grasp the burden of the whole course of lung cancer treatment. Therefore, the aim of
this study is to calculate the total cost of lung cancer treatment for lung cancer survivors in China
within five years from the date of diagnosis. The total cost includes direct costs and indirect costs.
In addition, we analyzed the payment of health insurance schemes on the direct medical costs and the
economic impact of lung cancer on the family income, information that could provide an objective
basis for health care policymaking.
2. Methods
2.1. Data Source
In this study, the sample was identified through the Nangang District Registry information system
of the Chinese National Central Cancer Registry [23]. From 2010 to 2014, 396 individuals survived
a diagnosis of lung cancer in 10 communities of Nangang District. Among them, 195 lung cancer patients
were finally enrolled in the study; the remainders were removed from the potential sample because of
the researchers’ inability to get follow-up data and/or patients’ refusal to participate. The retrospective
questionnaire survey was conducted with 195 surviving lung cancer patients or with their main family
caregivers to collect the information on sociodemographic characteristics, utilization of medical services,
and costs during illness. All of the respondents provided informed consent in writing.
2.2. Study Patient Identification
Cases included in the study were surviving patients who had been diagnosed with lung cancer
defined according to the International Classification of Disease 10th revision (ICD-10) codes from
C33-C34 [24].
2.3. Cost Classification and Definition
In this study, the economic burden of lung cancer was estimated by calculating direct medical costs,
direct nonmedical costs, and indirect costs covered in the five years following diagnosis. Direct medical
costs were expenditures on medical services and drugs associated with diagnosis and treatment
performed in hospitals, clinics, and pharmacies. These direct costs included three components:
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inpatient cost, outpatient cost, and purchased drug cost for lung cancer treatment paid by insurance,
co-payment, and non-insurance [25]. Direct nonmedical costs included transportation costs for a round
trip to visit health service providers and costs associated with accommodations, extra nutrition,
and hired escorts for lung cancer patients during the period of treatment in medical institutions.
Indirect costs were defined as days of lost productivity for both patients and their family caregivers
resulting from outpatient visits and hospitalization due to lung cancer [16].
2.4. Cost Estimation
The direct cost was calculated by summing the cost of the episodes of care in the period
considered in this study. Because the costs of treatments varied in different years, all the costs
were adjusted to 2014 to eliminate the effects of inflation using the annual consumer price index (CPI)
of Heilongjiang Province [26,27].
Indirect costs were measured using the human capital approach. The indirect costs were calculated
by multiplying the average daily wage income for an urban resident in Heilongjiang Province from
2010 to 2014 [16,28,29]. In China, the mandatory retirement age for men is 60, and, for women,
it is 50. Therefore, the productivity loss for patients and their families beyond this age range were not
considered in this study. Since the lost wages were considered over five years, a 3% inflation index was
used to convert past monetary values into present value in 2014 [6,30]. The Medical Ethics Committee
of Harbin Medical University (Daqing) agreed with this study and examined the project for related
medical ethics problems. The ethical project identification code is 16HMUSCI032.
3. Results
3.1. Description of Patient Sociodemographic Characteristics
As noted, 195 patients with lung cancer were eventually included in this study. Study participants
at the time of the survey were aged 29 to 89; 122 (62.56%) of them were male; 125 (64.10%) had retired,
22 (11.28%) were employed, and about a quarter were unemployed. No statistical significance was
found at the 5% level between respondents and identified patients not included in the sample by age
(p = 0.898) and gender (p = 0.311). Of the 195 patients included in the study, 157 respondents (80.51%)
were covered by various health insurance schemes and 38 (19.49%) were uninsured (Table 1).
Table 1. Sociodemographic characteristics of 195 lung cancer patients.
Sociodemographic Characteristics N
Male (n = 122) Female (n = 73)
Number Percent (%)/Mean Number Percent (%)/Mean
Age (years)
0–39 2 0 0.00 2 2.74
40–49 11 8 6.56 3 4.11
50–59 53 32 26.23 21 28.77
60–69 78 56 45.90 22 30.14
≥70 51 26 21.31 25 34.25
Marital status
Spinsterhood 1 1 0.82 0 0.00
Married/cohabitation 162 109 89.34 53 72.60
Divorce/separation 7 5 4.10 2 2.74
Widowed 25 7 5.74 18 24.66
Education status
Primary school or below 27 12 9.84 15 20.55
Junior school 80 56 45.90 24 32.88
Senior school/technical 63 35 28.69 28 38.36
College degree or above 25 19 15.57 6 8.22
Employment status
Employed 22 15 12.30 7 9.59
Unemployed 48 33 27.05 15 20.55
Retirement 125 74 60.66 51 69.86
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Table 1. Cont.
Sociodemographic Characteristics N
Male (n = 122) Female (n = 73)
Number Percent (%)/Mean Number Percent (%)/Mean
Quintile household per capita income (2014) ($)
Lowest 39 23 3541.72 16 4045.77
Low 39 26 5828.00 13 5633.55
Middle 39 24 6947.56 15 6941.10
Higher 39 23 9064.98 16 8821.72
Highest 39 26 14,637.02 13 14,354.52
Medical insurance
Yes 157 97 79.51 60 82.19
No 38 25 20.49 13 17.81
Purchasing power parity (PPP) was used in this study to convert RMB to dollars: $1 = 3.567 RMB (The PPP values
of RMB against the dollar in 2014) [31].
3.2. Economic Burden of Lung Cancer
3.2.1. Direct Medical Costs
The direct medical costs to the lung cancer patients in the study within five years after diagnosis
were $40,650 per patient, making up 93.80% of the total costs. The average total cost of outpatient
visits for those who made such visits was $1679 per patient, accounting for 3.87% of the average total
costs. In addition, the direct medical cost for hospitalization was $28,307 per lung cancer patient,
representing 65.32% of the total costs of treatment. The cost of drugs associated with lung cancer
treatment that were purchased from a pharmacy was $10,664 per patient, comprising 24.61% of the
total costs. In summary, hospitalization was the main component of the direct medical costs for lung
cancer patients, followed by the cost of purchased drugs (Table 2).
Table 2. Total economic burden of 195 lung cancer patients.
Type of Costs Costs ($) Cost per Patient ($)
95% Confidence Interval
%
Lower Limit Upper Limit
Direct medical costs
Outpatient 327,379.57 1678.87 1269.74 2088.00 3.87
Inpatient 5,519,906.27 28,307.21 24,337.95 32,276.48 65.32
Purchased drugs * 2,079,489.49 10,664.05 7521.11 13,806.99 24.61
Total 7,926,775.32 40,650.13 34,814.63 46,485.63 93.80
Direct nonmedical costs
Transportation 10,809.01 55.43 28.88 81.98 0.13
Accommodation 36,290.37 186.10 121.29 250.92 0.43
Nutrition 253,551.65 1300.26 1021.32 1579.21 3.00
Caregiver 6674.45 34.23 1.44 67.02 0.08
Other ** 61,269.82 314.21 200.46 427.95 0.73
Total 368,595.30 1890.23 1510.20 2270.27 4.36
Indirect costs
Patient 17,844.32 91.51 63.84 119.18 0.21
Family caregivers 137,268.71 703.94 614.12 793.77 1.62
Total 155,113.03 795.45 692.97 897.93 1.84
Total economic burden 8,450,483.65 43,335.81 37,329.58 49,342.05 100.00
* The cost of purchased drugs was the expense of the drugs that patients bought in pharmacies for their own lung
cancer treatment after the initial diagnosis. Expenditures for medicine prescribed by the doctors and purchased in
medical institutions were included in outpatient or inpatient costs; ** The other costs were estimated including the
cost of obtaining copies of medical records, the cost of special diets, special clothes, and wheelchairs for patients, etc.
$1 = 3.567 RMB (the PPP values of RMB against the dollar in 2014).
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3.2.2. Direct Nonmedical Costs
The average direct nonmedical cost was $1890 per patient, which accounted for 4.36% of total
costs (Table 2). The largest direct nonmedical cost was the nutrition costs, $1300 per patient, higher than
the accommodation costs and transportation costs.
3.2.3. Indirect Costs
The average indirect cost calculated as the lost productivity of patients and family caregivers was
$795 and represented the smallest share of overall costs at 1.84%. The average cost of lost productivity
was considerably higher for family caregivers ($704) than for the patients themselves ($92) (Table 2).
3.3. Influence of Medical Insurance on the Economic Burden of Lung Cancer Patients
A total of $7,926,775 was spent as direct medical costs for the 195 patients in the sample, $780,085
(9.84%) of which was paid by 38 noninsured patients. The direct medical costs for patients covered by
medical insurance were paid jointly by insurance and as copayments by insured patients. Of the total
direct medical expenditures for lung cancer, medical insurance paid for 22.98% of the outpatient costs,
48.86% of the hospitalization costs, and 2.59% of the costs of purchased drugs, respectively (Table 3).
Table 3. Medical expenditures payment by type of medical service.
Type of Service
Per capita Direct
Medical Costs ($)
(n = 195)
Paid by Insurer (n = 157) Paid by Patients ** (n = 157) Non-Covered *** (n = 38)
Per Capita
Costs ($)
Percent *
(%)
Per capita
Costs ($)
Percent *
(%)
Per capita
Costs ($)
Percent *
(%)
Outpatient 1678.87 479.24 22.98 1246.21 59.76 1486.42 17.25
Inpatient 28,307.21 17,179.75 48.86 14,196.67 40.38 15,626.5 10.76
Purchased drugs 10,664.05 343.41 2.59 12,075.04 91.17 3415.59 6.24
Total 40,650.13 18,002.40 35.66 27,517.92 54.50 20,528.55 9.84
Unit: USD; * Total cost paid by insurer or patients as a percent of total direct medical costs; ** Paid by the copayment
of insured patients; *** Non-covered refers to the costs for services paid by patients without any medical insurance.
Of the 195 lung cancer patients in the study, 157 participated in medical insurance schemes,
and the average reimbursement rate of direct medical costs for insured patients was 39.55%.
The highest reimbursement rate for direct medical costs was other types of insurance, which included
commercial medical insurance, two or more forms of medical insurance, and so forth. Of the
195 participants, 141 patients were covered by Urban Employees Basic Medical Insurance (UEBMI),
with a reimbursement rate of 39.39%, followed by the reimbursement rate of 38.14% from Urban
Residents Basic Medical Insurance (URBMI) (Table 4).
Table 4. Direct medical costs paid by type of medical insurance for insured patients.
Insurance Systems n Per Capita DirectMedical Costs ($)
Per Capita Cost Paid
by Insurance ($)
Reimbursement
Rate (%)
UEBMI 141 47,796.94 18,828.02 39.39
URBMI 8 28,685.56 10,941.92 38.14
Other types 8 22,229.71 10,511.34 47.29
Total 157 45,520.32 18,002.40 39.55
Unit: USD.
3.4. Impact of Economic Burden on the Family Economic Situation
The proportion of the economic burden of lung cancer treatment to household income during
the first year after diagnosis decreased from 171% to 107% after health insurance reimbursement.
The impact of the economic burden on the family economic situation varied with the quintile household
income. The results showed that the higher the household income, the lower the economic burden of
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lung cancer relative to household income. For the low- and middle-income households, the economic
burden of the first year’s treatment was still higher than the annual household income after the
reimbursement of medical insurance (Table 5).
Table 5. Influence of the financial burden in the first year after diagnosis on the family
economic situation.
Quintile
Household
Income
Average Household
Income for 2014
(USD/Household) (1)
Average
Economic Burden
(USD/Patient) (2)
Average
Reimbursement
(USD/Patient) (3)
The Proportion of the Economic Burden of
Household Income (%)
Before
Reimbursement (4)
After
Reimbursement (5)
Lowest 8083.07 19,073.03 4901.90 235.96 175.32
Low 12,854.30 30,650.86 11,855.12 238.45 146.22
Middle 16,684.28 34,316.62 14,103.15 205.68 121.15
Higher 20,870.80 26,960.39 10,390.47 129.18 79.39
Highest 29,882.90 40,382.12 15,138.53 135.13 84.48
Total 17,675.07 30,276.60 11,277.83 171.30 107.49
Note: Column 4 = column 2/column 1; column 5 = (column 2 − column 3)/column 1.
4. Discussion
This paper was designed to estimate the economic burden of lung cancer treatment within five
years from the date of diagnosis for lung cancer survivors in urban China. The total economic burden
was $43,336 per patient and was concentrated mainly in the first year after diagnosis. The study showed
that direct medical costs were the major component of the total economic burden of patients with lung
cancer. The average direct medical cost in the first year after diagnosis was $30,277. Prior studies that
estimated the direct economic burden of lung cancer inpatients showed that the average direct cost
ranged from $16,276 to $20,076 during the period of hospitalization in other areas of China [32–34].
These estimates are considerably lower than those identified in our study because their direct medical
costs were collected from medical records in specific hospitals only. Of the direct medical costs,
the proportion of hospitalization costs to the total economic burden of lung cancer was higher than
other costs. The average hospitalization cost that we estimated was $28,307, accounting for 65.32%
of the total economic burden, followed by purchased drugs, which accounted for 24.61%. The study
by Vasiliki et al. indicated that hospitalization costs ranged from 31% to 71% of total costs based on
findings from several other countries [16]. The results of our study suggest that more attention should
be paid to the management of hospitalization costs and to the cost of drugs from pharmacies for lung
cancer patients.
The average indirect cost found in this study was $795, accounting for 1.84% of the total economic
burden. This figure is probably an underestimate for several reasons. First, lost working days were
considered a time loss only during the treatment period; the days lost by patients and their families
during the recovery period were not included in our study due to lack of reliable data; Second,
productivity losses for males older than 60 and for females over 50, the official retirement ages in
China, were not calculated in the indirect cost. The relatively high ages of lung cancer patients might
account for the small indirect costs. Third, we estimated productivity lost by using the unified wage
standard without considering the different level of wages in different professions.
Although some costs are paid by medical insurance, the economic burden of the first year still
accounted for 107.49% of the average family annual income after the insurance compensation. All of
the families suffered catastrophic health expenditures, defined as out-of-pocket spending for health
care that exceeds 40% of a household’s income [35,36]. A study by Park et al. reported that the
cost for five-year lung cancer survivors constituted 44.7% of the per capita income during the same
period in a tertiary care hospital in South Korea in 2002 [15]. The results of our study showed that the
economic burden of lung cancer remains heavy, especially for low-income families in urban China.
Thus, the government needs to strengthen the Fiscal Medical Assistance for these lung cancer patients.
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Medical insurance played an important role in reducing the proportion of out-of-pocket expenses
in direct medical costs. In our study, more than one-third of the direct medical costs were paid by
medical insurance, and the costs paid by copayments of insured patients and noninsured patents
were 54.5% and 9.84%, respectively. In China, urban residents are covered mainly by two social basic
medical insurance systems: UEBMI, which covers employed urban residents, and URBMI, which is
designed to cover nonemployed urban residents, children, and students [37]. Combined, UEMBI and
URBMI covered about 71.35% of the urban population, with coverage rates of 39.30% and 32.04%,
respectively, in Heilongjiang Province in 2014 [38]. The results of this study showed slightly different
reimbursement ratios for lung cancer patients: 39.39% for UEBMI and 38.14% for URBMI patients.
Of the 157 patients with health insurance, the reimbursement rate of health insurance was 39.55%,
and the remaining 60.45% of direct medical costs were paid Out-of-Pocket. The high copayment
for current health insurance schemes needs to be reduced to avoid the occurrence of catastrophic
health expenditures.
This analysis has several limitations. First, the recall bias of respondents in reviewing the costs
could not be avoided due to the retrospective investigation in the community; Second, because this
study included only survivors of lung cancer, the indirect costs consisted of only the productivity
loss caused by delays, and not the cost of lost productivity due to premature mortality, which could
greatly undervalue the indirect economic burden of illness [39,40]. The lack of data on productivity
lost by patients and caregivers during the recovery period could also underestimate the indirect cost
estimates; Third, intangible economic costs to the psychological and mental health of lung cancer
patients and their caregivers, such as the pain, sorrow, and inconvenience due to the decline in quality
of life, were not included because they are difficult to convert into a monetary value [41]; Finally,
the variety of clinical types and stages of lung cancer were not taken into account because of a lack of
data, but they comprise a topic worthy of further studies.
5. Conclusions
From the perspective of the survival of individuals with lung cancer, this study showed that the
costs of lung cancer are substantial compared to the patients’ household income. The economic burden
of lung cancer patients is attributed mainly to direct costs in the urban areas of China. Furthermore,
the largest component of the total economic burden was the cost of hospitalization. Indirect costs were
considerably higher for family caregivers than for patients themselves and represented a relatively
small proportion of the total economic burden. Although medical insurance paid on average 40%
of the total direct medical cost for insured patients, the proportion of out-of-pocket expenses was
still too high. The economic burden for lung cancer patients was heaviest in the first year following
diagnosis and was likely to induce catastrophic health expenditures for households, especially those
low- and middle-income families. To further reduce the health care economic burden, increased and
well-targeted subsidies for low-income patients are needed.
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